YERVOY SINJ 200MG 40ML 1VLX

How It Works

YERVOY SINJ contains the active ingredient ipilimumab, which is a monoclonal antibody that targets cytotoxic T-lymphocyte antigen-4 (CTLA-4), a protein receptor found on the surface of T cells. By inhibiting CTLA-4, YERVOY SINJ enhances the activation and proliferation of T cells, which are important components of the immune system involved in fighting cancer cells. This immune activation leads to an anti-tumor response, allowing the immune system to recognize and destroy cancer cells more effectively.

Side Effects

Fatigue

Diarrhea

Rash

Pruritus (itching)

Colitis (inflammation of the colon)

Hepatitis (inflammation of the liver)

Endocrinopathies (e.g., hypothyroidism, hyperthyroidism)

Indications

YERVOY SINJ is indicated for the treatment of:

Advanced melanoma (skin cancer)

Unresectable or metastatic melanoma (in combination with nivolumab)

Advanced renal cell carcinoma (kidney cancer)

Microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer

Contraindications

Hypersensitivity to ipilimumab or any component of the formulation

Severe or life-threatening immune-related adverse reactions

Active autoimmune disease that requires systemic immunosuppression

Price Comparison in Different Countries

Country Price (per vial) Website

United States $20,000 GoodRx

United Kingdom £16,000 NHS

Australia AUD 24,000 Chemist Warehouse

Canada CAD 21,000 Canada Drugs Direct

Germany €17,000 Apotheken Umschau

Top 5 Global Brands

Bristol-Myers Squibb

Merck & Co.

Roche

Novartis

Johnson & Johnson